Target type: biologicalprocess
The series of events in which information about the density of cells in a population is received by direct cell-cell contact and is converted into a molecular signal, resulting in the cessation of cell growth or proliferation. [GOC:dph, PMID:17376520]
Contact inhibition is a fundamental process in multicellular organisms that regulates cell growth and movement. It prevents cells from growing uncontrollably and invading surrounding tissues, contributing to the maintenance of tissue homeostasis and preventing tumor formation. Here's a detailed description of the biological process:
**1. Cell-Cell Contact:** The process begins with the physical interaction between cells. As cells grow and divide, they come into contact with neighboring cells. This contact triggers signaling pathways within the cells, leading to changes in their behavior.
**2. Signaling Pathways:** Several signaling pathways are involved in contact inhibition, including:
* **Cadherin-mediated cell adhesion:** Cadherins are transmembrane proteins that mediate cell-cell adhesion. When cells come into contact, cadherins bind to each other, forming a strong adhesive junction. This binding activates downstream signaling pathways.
* **Growth Factor Signaling:** Contact inhibition can also involve the downregulation of growth factors, such as epidermal growth factor (EGF). When cells are in contact, they may secrete less growth factor, or the growth factor receptors on the cell surface may become less sensitive to the factor.
* **Other signaling pathways:** Other signaling pathways, such as the Hippo pathway and the Ras pathway, can also contribute to contact inhibition.
**3. Cell Cycle Arrest:** One of the key outcomes of contact inhibition is cell cycle arrest. When cells are in contact, they typically enter the G1 phase of the cell cycle, where they cease dividing and remain in a quiescent state. This arrest is mediated by the regulation of key cell cycle proteins, such as cyclin-dependent kinases (CDKs) and their inhibitors.
**4. Changes in Cell Morphology:** In addition to cell cycle arrest, contact inhibition can also lead to changes in cell morphology. For example, cells may become more flattened or elongated, and their cytoskeletal organization may be altered. These changes can affect cell movement and migration.
**5. Role in Development and Cancer:** Contact inhibition is crucial for normal development and tissue homeostasis. During embryonic development, contact inhibition ensures that cells grow and divide in an organized manner, forming the correct tissues and organs. In adults, contact inhibition helps to maintain the integrity of tissues and prevent uncontrolled cell growth. When contact inhibition is disrupted, it can contribute to the development of cancer. Cancer cells often lose their ability to respond to contact inhibition, allowing them to grow uncontrollably and invade surrounding tissues.
**6. Role in Wound Healing:** While contact inhibition typically inhibits cell growth, it can also play a role in wound healing. In the early stages of wound healing, cells may migrate to the wound site without being inhibited by contact, allowing for rapid closure of the wound. Once the wound is closed, contact inhibition is re-established to prevent excessive scarring.'
"
Protein | Definition | Taxonomy |
---|---|---|
Smoothened homolog | A protein smoothened that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99835] | Homo sapiens (human) |
Receptor-type tyrosine-protein phosphatase eta | A receptor-type tyrosine-protein phosphatase eta that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q12913] | Homo sapiens (human) |
Translocator protein | [no definition available] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
pk 11195 | PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine | aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes | antineoplastic agent |
ro 5-4864 | 4'-chlorodiazepam: selectively binds peripheral benzodiazepine receptor | ||
clonazepam | clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation. Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses. | 1,4-benzodiazepinone; monochlorobenzenes | anticonvulsant; anxiolytic drug; GABA modulator |
nordazepam | nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety. Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam. | 1,4-benzodiazepinone; organochlorine compound | anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative |
diazepam | diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5. Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity. | 1,4-benzodiazepinone; organochlorine compound | anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic |
flunitrazepam | flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia. Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. | 1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes | anxiolytic drug; GABAA receptor agonist; sedative |
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone | ZM39923: structure in first source | naphthalenes | |
beta-lapachone | beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities. beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase | benzochromenone; orthoquinones | anti-inflammatory agent; antineoplastic agent; plant metabolite |
lorazepam | Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent. | benzodiazepine | |
vitamin k 3 | Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo. | 1,4-naphthoquinones; vitamin K | angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical |
nitrazepam | nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome). Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic. | 1,4-benzodiazepinone; C-nitro compound | anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative |
cm 7116 | norflutoprazepam: structure | benzodiazepine | |
oxazepam | oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5. Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia. | 1,4-benzodiazepinone; organochlorine compound | anxiolytic drug; environmental contaminant; xenobiotic |
temazepam | Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent. | benzodiazepine | |
chlordesmethyldiazepam | benzodiazepine | ||
halazepam | halazepam: structure | organic molecular entity | |
alpidem | imidazoles | ||
n-desmethylflunitrazepam | |||
7-aminonitrazepam | 7-aminonitrazepam: urinary metabolite of nitrazepam | benzodiazepine | |
ro 20-1815 | 7-aminoflunitrazepam: flunitrazepam metabolite; structure given in first source | benzodiazepine | |
dx 9065 | |||
celastrol | monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite | |
ro 11-6893 | Ro 11-6893: RN given refers to (R)-isomer | ||
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide | N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide: binds with high affinity to glial mitochondrial diazepam binding inhibitor receptors & increases mitochondrial steroidogenesis | phenylindole | |
7-aminoclonazepam | benzodiazepine | ||
ro 5-3438 | Ro 5-3438: structure | ||
nsc 95397 | 1,4-naphthoquinones | ||
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
pd 173955 | PD 173955: inhibits src family-selective tyrosine kinase; structure in first source | aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine | tyrosine kinase inhibitor |
n-desmethylflunitrazepam | N-desmethylflunitrazepam: metabolite of flunitrazepam | ||
ro 05-4082 | ID 690: methyl deriv of clonazepam; structure | ||
ag-213 | tyrphostin 47: inhibits protein-tyrosine kinase activity of EGF-R both in vitro and in living cells; | ||
rottlerin | rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis. rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1); | aromatic ketone; benzenetriol; chromenol; enone; methyl ketone | anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite |
purmorphamine | purmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group. purmorphamine: structure in first source | aromatic ether; morpholines; purines; secondary amino compound | osteogenesis regulator; SMO receptor agonist |
gw-5074 | |||
ac-5216 | |||
cb 34 | CB 34: ligand for peripheral benzodiazepine receptors; structure in first source | ||
n-(2-methoxybenzyl)-n-(4-phenoxypyridin-3-yl)acetamide | N-(2-methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide: for imaging brain peripheral benzodiazepine receptors; structure in first source | ||
ssr180575 | SSR180575: structure in first source | ||
cur 61414 | CUR 61414: inhibits the hedehog signaling pathway; structure in first source | ||
daa 1106 | |||
naluzotan | naluzotan: an antidepressant and anti-anxiety agent; structure in first source | ||
abt 869 | aromatic amine; indazoles; phenylureas | angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | |
dpa-713 | |||
a 803467 | A 803467: an Nav1.8 sodium channel blocker; structure in first source | ||
lde225 | sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma. sonidegib: specific Smoothened/Smo antagonist | aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound | antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist |
gdc 0449 | HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity | benzamides; monochlorobenzenes; pyridines; sulfone | antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent |
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide | thioureas | ||
ipi-926 | IPI-926: a semisynthetic derivative of cyclopamine that is a smoothened inhibitor with antineoplastic activity; structure in first source | piperidines | |
n-fluoroacetyl-n-(2,5-dimethoxybenzyl)-2-phenoxyaniline | N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline: a peripheral benzodiazepine receptor PET ligand; structure in first source | ||
gsk 1363089 | GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source | aromatic ether | |
tak-441 | TAK-441: structure in first source | ||
ly2940680 | |||
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | BGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor. infigratinib: structure in first source | aminopyrimidine; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas | antineoplastic agent; fibroblast growth factor receptor antagonist |
cep-32496 | agerafenib: inhibitor of RAF family kinases; structure in first source | ||
pf-5274857 | 1-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source | ||
MS-417 | MS-417 : A member of the class of thienotriazolodiazepines that is the methyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. A bromodomain and extra-terminal domain (BET)-specific inhibitor that belongs to a group of thienodiazepine-based compounds | methyl ester; monochlorobenzenes; thienotriazolodiazepine |